NLRP1 and Alzheimer disease: While the precise role of caspase-1 in AD neuropathology remains unclear, compelling evidence suggests that targeting caspase-1 could be a viable therapeutic approach for addressing AD and possibly other tauopathies [58], alone or combination with drugs targeting Nlrp1 and caspase-6 [59].